BlackRock’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-235,879
| Closed | -$245K | – | 5197 |
|
|
2019
Q1 | $245K | Buy |
235,879
+8,242
| +4% | +$6.71K | ﹤0.01% | 4213 |
|
|
2018
Q4 | $169K | Sell |
227,637
-13,566
| -6% | -$20.4K | ﹤0.01% | 4267 |
|
|
2018
Q3 | $510K | Buy |
241,203
+3,064
| +1% | +$7.34K | ﹤0.01% | 4134 |
|
|
2018
Q2 | $550K | Buy |
238,139
+17,133
| +8% | +$49.9K | ﹤0.01% | 4072 |
|
|
2018
Q1 | $702K | Sell |
221,006
-3,151
| -1% | -$8.68K | ﹤0.01% | 3969 |
|
|
2017
Q4 | $919K | Sell |
224,157
-568,181
| -72% | -$2.47M | ﹤0.01% | 3919 |
|
|
2017
Q3 | $3.58M | Buy |
792,338
+10,565
| +1% | +$42.8K | ﹤0.01% | 3560 |
|
|
2017
Q2 | $2.6M | Sell |
781,773
-912,592
| -54% | -$3.79M | ﹤0.01% | 3623 |
|
|
2017
Q1 | $15.6M | Buy |
1,694,365
+1,692,635
| +97,840% | +$14.9M | ﹤0.01% | 2903 |
|
|
2016
Q4 | $13K | Sell |
1,730
-165
| -9% | -$1.52K | ﹤0.01% | 3353 |
|
|
2016
Q3 | $21K | Buy |
1,895
+419
| +28% | +$4.88K | ﹤0.01% | 3281 |
|
|
2016
Q2 | $18K | Buy |
1,476
+245
| +20% | +$2.97K | ﹤0.01% | 3304 |
|
|
2016
Q1 | $12K | Buy |
1,231
+656
| +114% | +$7.7K | ﹤0.01% | 3099 |
|
|
2015
Q4 | $13K | Buy |
575
+280
| +95% | +$5.74K | ﹤0.01% | 2795 |
|
|
2015
Q3 | $5K | Hold |
295
| – | – | ﹤0.01% | 3067 |
|
|
2015
Q2 | $7K | Hold |
295
| – | – | ﹤0.01% | 3049 |
|
|
2015
Q1 | $8K | Hold |
295
| – | – | ﹤0.01% | 2893 |
|
|
2014
Q4 | $6K | Hold |
295
| – | – | ﹤0.01% | 3043 |
|
|
2014
Q3 | $6K | Hold |
295
| – | – | ﹤0.01% | 3058 |
|
|
2014
Q2 | $7K | Buy |
+295
| New | +$7.28K | ﹤0.01% | 3052 |
|
BlackRock's OMED Position: Q2 2019 in Review
BlackRock sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 235,879 shares — an estimated $245K sold.
BlackRock first reported a position in OMED in Q2 2014 and held it in 20 quarters. The position peaked at $15.6M in Q1 2017. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- BlackRock reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- BlackRock sold 235,879 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $245K.
- BlackRock first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2014 and held it in 20 quarters.
- BlackRock's OncoMed Pharmaceuticals, Inc. position peaked at $15.6M in Q1 2017.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on BlackRock's 13F filing for Q2 2019, filed 13 Aug 2019.